Kenn jemand Xoma... - 500 Beiträge pro Seite

[Minolta]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[BigLinus]

Hi Minolta,

ließ den Thread Biotechwert XOMA steigt, ...

Ciao

[Minolta]

Hi!
Auf Xoma bin ich in einer Zeitschrift über Bio-Werte aufmerksam geworden. Anfang des Jahres im Kleingedruckten. Ich meine, es war die Telebörse. Xoma hat seinen Sitz auf Bermuda und die Wkn: 871239
Momentan evtl. Aussicht auf ein neues Krebsmittel und zahlreiche andere. Habe letzte Woche nochmal nachgekauft. Denke man kann noch günstig einsteigen. Aber wie lange noch? Wie bei allen Bio-Werten ge-hört natürlich auch eine Portion Glück dazu, den "richtigen" zu finden. Ich bin von Xoma fest überzeugt. Gruß an alle Xomas, Minolta

[BigLinus]

Hi Minolta,

auch hierzu kann ich Dir nur den Thread `Biotechwert XOMA steigt ...` empfehlen.

Sie die dort genannten Kursziele für Dich in Ordnung bzw. realistisch, dann ist auch noch der Kauf bei 20 EUR akzeptabel. Jedoch sind die möglichen Bauchschmerzen hier dann deutlich höher.

Ciao

[Minolta]

Hi, BigLinus!
Danke für den Hinweis, kann "Biotech-Xoma..." aber nicht finden. Übersehen?

[GeldFuchs]

Hallo Minolta

Xoma wurde in der Börse-Online erwähnt mit dem Titel "1500 Fonds ..."
gelaube es war die vovor-letzte Asugabe.

Um Threads dazu zu finden gib XOMA ins Feld ein und drücke auf
Stichwort oder auf Aktie wie du willst .. je nach Infowunsch.

Firma forscht auch im Bereich Proteine ...

habe selber auch xoma
gruß geldfuchs

[Minolta]

Danke geldfuchs! Stimmt mich alles sehr hoffnungsvoll

[MasterEd]

Avant, British Bio und Xoma sind meine 3 Highflyer 2000!
Gute Wahl Jungs!!!

Weiter so!

www.xoma.com

Bio-Ed

[Greenshook]

Hallo liebe Leute,
auch in meinen Augen ist Xoma ein zukunftsträchtiger Wert.

Hier einige Facts zum Unternehmen: (www.xoma.com)


Investor Fact Sheet
November 1999
Nasdaq: XOMA
Recent stock price: $3.00 (11/30/99)
Common shares outstanding: 55.6 million (9/30/99)
Market capitalization: $166.7 million (11/30/99)
Cash and investments: $22.3 million (9/30/99)
Average daily volume: 542,075 (12/98-11/99)
Fiscal year end: December 31st
Domicile: Bermuda
Operations: Berkeley and Santa Monica, California USA
Employees: 175 (11/30/99)


XOMA develops and manufactures genetically-engineered protein (including antibody) and peptide pharmaceuticals. Medical targets include microbial infections, infectious complications (such as those that may follow trauma or surgery), and immunologic disorders. The Company’s primary drug development platform is BPI (bactericidal/permeability-increasing protein), a human host-defense protein with multiple anti-infective properties.

The BPI Platform has several products in development (see pipeline inside). NEUPREX®, XOMA’s first recombinant BPI-derived product, has recently completed a Phase III trial in severe pediatric meningococcemia. An ophthalmic anti-infective development effort has led to a recent license to Allergan to use recombinant BPI (rBPI) in combination ophthalmic anti-infectives with antibiotics. Additional BPI-derived formulations (e.g., “I-PREX”), are under development for other ophthalmic indications. XOMA is actively seeking a partner for clinical development of its BPI-derived antifungal peptido-mimetics (“Mycoprex”). Additional BPI-derived products are in the research pipeline, including anti-angiogenic and anti-infective compounds.

The Company has considerable experience with therapeutic antibody development. In a unique collaboration, Genentech and XOMA have successfully brought the anti-CD11a (hu1124) antibody through Phase II clinical trials in moderate-to-severe psoriasis patients and started Phase III trials. Clinical testing is also planned in kidney transplant rejection patients. Other XOMA antibodies include ING-1 (targeting cancers) and a targeted immunfusion (TIF) protein, Genimune™ (targeting immunological disorders). XOMA’s patented Human Engineering technology represents a new alternative to CDR-grafting methods for humanization of antibodies.

Three partners in the United States and Japan are developing diagnostics based on XOMA’s LBP (lipopolysaccharide binding protein) assay. XOMA has also granted 17 licenses for its bacterial cell expression system for the manufacture of recombinant proteins. Additional transactions include T cell receptor technology sold to Connetics and anti-CD20 patents licensed to Genentech for IDEC’s Rituxan® product. Over the last three years, XOMA has raised more than $70 million in cash from such arrangements and the Genentech collaboration

XOMA’s business strategy is to develop and manufacture its compounds through human clinical trials and partner products for commercialization and marketing. Therefore, the Company maintains a manufacturing infrastructure for product development from the laboratory to commercial scale.

At the end of 1998, XOMA changed its legal domicile from Delaware to Bermuda (becoming XOMA Ltd.). A wholly owned subsidiary, XOMA (US) LLC, continues to operate the administrative, research & development and manufacturing activities in Berkeley, California, as well as manufacturing research and scale-up facilities located in Santa Monica, California.

XOMA Product Development Pipeline
Trade Name Product Description Indication Status Comments
rBPI-21 IV formulation
(NEUPREX®) meningococcemia Phase III 395 patients, enrollment complete
hemorrhage due to trauma Phase III Halted at 1100 patients
severe intra-abdominal infections Phase I/II dose-related benefits in 21 patients
partial hepatectomy Phase II 35 patient study, article submitted
pulmonary exacerbations in cystic fibrosis patients Phase I 15-patient PK/safety study complete
rBPI-21 combination topical
anti-infectives ophthalmic infections, corneal ulcers Preclinical licensed to Allergan
rBPI-21 topical formulation
(I-PREX(tm)) ophthalmic infections prophylaxis Preclinical Strategic partner discussions
BPI-Derived Peptides fungicidal compounds (Mycoprex(tm)) systemic fungal infections Preclinical Strategic partner discussions
anti-angiogenic chronic infalmmatory diseases, metastatic tumors Preclinical Internal program
antibacterial gram-negative and gram-positive infections Research Internal program
anti-endotoxin endotoxin neutralization Research Internal program

Lipopolysaccharide
Binding Protein (LBP) diagnostic assay endotoxin-associated disorders Clinical Licensed to Biosite, DPC and SRL
hu1124
(Anti-CD11a) humanized monoclonal
antibody moderate to severe
psoriasis Phase II Collaboration with Genentech
kidney transplant rejection Pre-IND Collaboration with Genentech
Expression Technology bacterial and CHO cell expression/secretion systems recombinant protein manufacturing production system Available for licensing 17 licenses to date
Human
Engineering antibody humanization therapeutics Available for licensing Altenative to CDR grafting
ING-1 therapeutic antibody cancer therapeutics and diagnostics Available for licensing Humanization in process
Gelonin Fusion Proteins TIF (targeted immunofusion) (Genimune(tm)) autoimmune disorders
Immunological cancers Available for licensing Strategic partner discussions
Thaumatin recombinant plant-derived protein flavor enhancer FEMA GRAS Approved Available for outlicensing.

Übrigens:
Xoma wurde vor kurzem bei Bloomberg TV als aussichtsreicher Biotechwert empfohlen !

Auf das wir Ende des Jahres über die jetzigen Kurse lachen können...

Gruß an alle Xoma`s
Greenshook

[Greenshook]

Zur Zeit ideale Einstiegskurse...

[kimjan1]

Gibt es hier jemanden, der die englischen Kommentare (posted von Greenshook) über Xoma verstanden hat?

Ich würde die Inhalte und Perspektiven gerne mit jmd diskutieren, der "vom Fach" ist, d h gelernte Biologen (so einer bin ich), Biochemiker, Mediziner, Immunologen o ä "Forscherpack"

Meine email [e-mail]

[BigLinus]

`BioTech`-Neuemissionen
IPO Forecast 03/24/00 3:30 PM
By Kelly Black


Allos Therapeutics (ALTH)

Expected IPO date: March 28
Proposed offering price: $17-$19
Shares offered: 5.0 million
Offering amount: $90 million
Post-offering shares: 22.8 million
Lead underwriter: SG Cowen

Summary: Allos Therapeutics is a pharmaceutical company that develops cancer fighting small-molecule drugs. Its flagship product RSR13 makes solid tumors susceptible to radiation therapy.

Competitors: Trega Biosciences (TRGA), NeoRx (NERX), Vaxel (VXCL)
Revenue (year ended December 31): $0
Net income (year ended December 31): $11.3 million loss

----------------------------------------------------------------------


DrugAbuse Sciences (DASI)

Expected IPO date: March 28
Proposed offering price: $13-$15
Shares offered: 4.0 million
Offering amount: $56 million
Post-offering shares: 16.5 million
Lead underwriter: Warburg Dillon Read

Summary: A biotech company that develops timed-release drugs used in the treatment of alcohol and drug addictions The company currently has a receptor blocking drug NALTREL in clinical trials to aid in the treatment of heroin addiction.

Competitors: Schering-Plough (SGP), American Home Products (AHP), Merck
Revenue (year ended December 31): $1.2 million
Net income (year ended December 31): $6.2 million loss

----------------------------------------------------------------------


IntraBiotics Pharmaceuticals (IBPI)

Expected IPO date: March 28
Proposed offering price: $13-$15
Shares offered: 7.5 million
Offering amount: $105 million
Post-offering shares: 28.58 million
Lead underwriter: DB Alex Brown

Summary: The company develops new antibacterial and antifungal drugs used to fight deadly bacteria and prevent serious infectious diseases. IntraBiotics is also currently developing Protegrin IB-367, an oral rinse designed to reduce mouth ulcers in cancer patients.

Competitors: Pharmacia & Upjohn (PNU), Schering-Plough (SGP), Aventis (AVE)
Revenue (year ended December 31): $7.8 million
Net income (year ended December 31): $23.1 million loss

----------------------------------------------------------------------


Luminex (LMNX)

Expected IPO date: March 30
Proposed offering price: $17-$19
Shares offered: 4.5 million
Offering amount: $100 million
Post-offering shares: 26.5 million
Lead underwriter: Warburg Dillon Read

Summary: The company developed and manufactures the Luminex 100, a proprietary technology platform used to simply perform nearly 100 biological tests for the life sciences industry.

Competitors: Endogen, Aurora Biosciences (ABSC), LJL BioSystems (LJLB)
Revenue (year ended December 31): $3.1 million
Net income (year ended December 31): $8.4 million loss

----------------------------------------------------------------------


Rigel Pharmaceuticals (RIGL)

Expected IPO date: March 28
Proposed offering price: $10-$12
Shares offered: 9.0 million
Offering amount: $99 million
Post-offering shares: 37.6 million
Lead underwriter: Warburg Dillon Read

Summary: Rigel Pharmaceuticals is a post-genomics combinatorial biology company that uses retroviruses to find novel drug targets and validate the role of those targets in disease.

Competitors: Immunex (IMNX), Centocor, Aventis (AVE)
Revenue (year ended December 31): $8.98 million
Net income (year ended December 31): $12.4 million loss

[fati]

Hilfe!!!

Ich habe ein Problem, jede Bewertung die ich gelesen habe ist positiv,
aber die Aktie fällt und fällt und fällt.... Meine Frage nun, warum fällt die Aktie und warum sind alle Aussage positiv.

[mahatma]

schau schau an !!!!!!!!
Xoma heute am Nasdaq im Plus (2,8 %)
Nerven behalten , wie Freund Helmut von der Politik

[MasterEd]

Also Fati, ist dir schon mal was zu Ohren gekommen, das Biotech momentan nur auf die Ohren kriegt???
Viele werden im Sog mitgezogen!
Ich lache darüber und kaufe zum rechten Zeitpunkt wieder,
ich habe vor Wochen mit 200% Gewinn verkauft!
Das sind Einstiegskurse, mein Freund, umgangssprachlich "Schnäppchen" genannt!
Ich sehe das Kursziel Ende 2000 auf 40-50 Euro!!!

Biotech ist nix für Schwächlinge, cool bleiben...abwarten...
kuck dir mal an wo die heutigen grossen Bio´s stehen und wie sie angefangen haben!!! Kurzfristig ist da im Moment nix zu grosses zu holen!!! Mittel- bis langfristig denken! Früh dabei sein ist alles!
Ich bin sehr optimistisch mit XOMA und den anderen >>>AVANT, STRESSGEN, BRITISH BIOTECH, BIOTRACE<<<

Gruß,
Bio-Ed

[Greenshook]

Master Ed,

Du schreibst mir aus der Seele.
Unsere Zeit wird kommen!
Geduld hat sich schon immer ausgezahlt...

Gruß
Greenshook